Over 3 Million Dollars Available for Young Scientists

06.19.14 | By

For nearly 50 years the PhRMA Foundation has helped thousands of scientists advance their careers and has inspired new generations to enter biopharmaceutical research. The early-career support provided by the PhRMA Foundation has been a catalyst for scientists to become leaders in their organizations and fields. Their programs help build a larger pool of highly-trained researchers to meet the growing needs of academic institutions, the government and the research-intensive pharmaceutical industry. Are you one of them?

Understanding Health Insurance Exchanges State-by-State

06.19.14 | By

It’s no secret that when it comes to the Affordable Care Act, health insurance exchange coverage varies depending on where you live. From the plans offered, to premiums, to the type of Marketplace, not every state looks alike.

That’s why we created state-by-state fact sheets on health insurance exchange coverage and access to prescription medicines across the country.

First Technology Pilot Program Shares Perspective of Sickle Cell Disease Community with FDA

06.18.14 | By

In the guest blog below, Michele Lloyd-Puryear, Special Consultant to Genetic Alliance, discusses key findings from a patient-driven data collection effort intended to complement the Food and Drug Administration’s (FDA) patient-focused drug development initiative which was part of the most recent reauthorization of the Prescription Drug User Fee Act.

More than 430 Medicines in Development to Treat Chronic Diseases Affecting Older Americans

06.18.14 | By

Aging is a fact of life but the good news is that life expectancy continues to climb and more and more Americans are living fuller, richer lives thanks in large part to innovative medicines being developed by biopharmaceutical companies. As the baby boomer generation reaches retirement age, the demands on our health care system will continue to rise due to the increasing prevalence of chronic diseases affecting seniors.

Charles River Associates Releases Updated HTA Comparison Report

Washington, D.C., Brussels (June 17, 2014) — Charles River Associates today announced the release of a report at the HTAi Annual Meeting titled “A Comparative Analysis of the Role and Impact of Health Technology Assessment.”  The report, commissioned by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA), updates a previous study conducted in 2011. 

Patient Reported Outcomes as a Means to Reaching Effective Quality Measurement

06.17.14 | By

A recent Roundtable in Washington D.C. underscored why, with the growing focus on value-based payment in health care, it’s more important than ever to focus on the patient. We can’t advance patient-centered care if we aren’t measuring and incentivizing what matters to patients. We have begun to see this shift in the premarket arena via patient-focused drug development and in comparative effectiveness research at the Patient-Centered Outcomes Research Institute.

A Mother’s View: Value and Cost of Health Care

06.17.14 | By

Over the last three years, I have had two c-sections – one for the birth of my 3-year old daughter and the other for the birth of my six-month old twins.  Fortunately, I have good health insurance coverage through my employer and didn’t have to pay a lot out of pocket for these necessary procedures. The more than $20,000 price tag for the single procedure was almost fully covered and I was happy that I could focus all of my attention on my newborn babies rather than figure out how I’m going to pay my  bills.

State “Right-to-Try” Legislation, While Well-Intentioned, Is Unlikely to Achieve Goal of Bringing Safe and Effective New Medicines to Patients

06.14.14 | By

The development of innovative, safe, and effective medicines for serious or life-threatening diseases represents an urgent and unique challenge that requires special attention.

Week in Review: The Obstacles to Patient Care Under HIX

06.13.14 | By

For our nation’s most vulnerable patients, access to necessary medicines to treat and even cure the diseases they are battling every day is critical. Improved patient health relies on the innovative treatments, and this week we focused on the importance of ensuring those medicines make it into the hands of patients in need.

Working Together for the Greater Good: The Current State of the Collaborative Research Ecosystem in Oncology

06.12.14 | By

Keeping the spirit of innovation alive in the oncology field is paramount to future scientific advances and finding cures. An essential element of innovation is collaboration. Relevant stakeholders coming together and pooling collective knowledge together can ignite the fire that becomes the next big thing to improve the lives of cancer patients.

Pages

Subscribe to RSS - Opinion